Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: The Himmel Group

This article was originally published in The Rose Sheet

Executive Summary

The Himmel Group: Retains TM Capital Corp. to investigate new branded consumer product "opportunities." Himmel, which markets the Ovaltine powdered drink mix, is interested in personal care items, cosmetics, OTC drugs, foods, beverages, household products and pet supplies/food items. Products of interest would have sales of up to $100 mil., be "advertisable" on TV and radio and have retail distribution through channels including food and grocery stores, mass merchandisers, club stores and drug stores. Himmel would consider "collaboration structures" including acquisitions, licensing, incentive market and media arrangements. The company exited the H&BA market in 1996 when it sold the Gold Bond Medicated Powder line to Chattem for $40 mil. ("The Rose Sheet" April 15, 1996, p. 7)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS004853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel